Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Buprenorphine

FDA-approved product (film, extended release, transdermal), marketed as Brixadi, Buprenorphine, Butrans and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Buprenorphine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic pain
  • Drug dependence
  • Opioid dependence
  • Opioid use disorder
  • Overdose
  • Pain
  • Substance abuse

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Oripavine derivatives; Drugs used in opioid dependence
FDA pharmacologic class
Partial Opioid Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Buprenorphine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not docked: the structure could not be prepared for dockingdetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not docked: the structure could not be prepared for dockingdetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not docked: the structure could not be prepared for dockingdetails

Dihydrofolate reductase ↗ (MRSA)

Not docked: the structure could not be prepared for dockingdetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Buprenorphine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pioglitazone to Treat Opioid Withdrawal Symptoms

    NCT01517165 · start 2012-01-04

    Registered record
    Registry ID
    NCT01517165
    Conditions
    Opioid-Related Disorders
    Interventions
    Pioglitazone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2012-01-04
    Completion
    2015-02-02
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-Related Disorders
    InterventionPioglitazone; Placebo
    PhasePhase 1
    Registry statusTerminated

  • HIV Risk Reduction in Subutex Injectors in Tbilisi

    NCT01131273 · start 2010-06

    Registered record
    Registry ID
    NCT01131273
    Conditions
    HIV
    Interventions
    methadone; buprenorphine-naloxone (Suboxone) for 12 weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-06
    Completion
    2013-08
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventionmethadone; buprenorphine-naloxone (Suboxone) for 12 weeks
    PhasePhase 3
    Registry statusCompleted

  • A Study to Characterize the Pharmacokinetics and Tolerability of Buprenorphine Patches in Children With Moderate to Severe Mouth Pain

    NCT00947466 · start 2010-02

    Registered record
    Registry ID
    NCT00947466
    Conditions
    Chemotherapy Induced Mucositis; Mouth Pain
    Interventions
    Buprenorphine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2010-02
    Completion
    2012-11
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy Induced Mucositis; Mouth Pain
    InterventionBuprenorphine
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts

    NCT01668706 · start 2009-03

    Registered record
    Registry ID
    NCT01668706
    Conditions
    Heroin Dependence
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-03
    Completion
    2013-12
    Enrolment
    340

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeroin Dependence
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Study of Probuphine in Patients With Opioid Dependence

    NCT00772785 · start 2008-09

    Registered record
    Registry ID
    NCT00772785
    Conditions
    Opioid Dependency
    Interventions
    Probuphine (buprenorphine implant)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2008-09
    Completion
    2009-02
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Dependency
    InterventionProbuphine (buprenorphine implant)
    PhasePhase 3
    Registry statusTerminated

  • Buprenorphine Naltrexone-P1 A-Cocaine

    NCT00733720 · start 2008-08

    Registered record
    Registry ID
    NCT00733720
    Conditions
    Cocaine-related Disorders
    Interventions
    Suboxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-08
    Completion
    2009-01
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine-related Disorders
    InterventionSuboxone
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of Neurocognitive Performance in Drug Substituted Patients Under Hepatitis C Therapy

    NCT00682591 · start 2008-07

    Registered record
    Registry ID
    NCT00682591
    Conditions
    Chronic Hepatitis C Infection
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2008-07
    Completion
    2011-12
    Enrolment
    190

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C Infection
    InterventionNot recorded
    PhaseNot recorded
    Registry statusWithdrawn

  • A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)

    NCT00604188 · start 2008-02-22

    Registered record
    Registry ID
    NCT00604188
    Conditions
    Opiate Dependence; Drug Dependence; Substance Dependence
    Interventions
    Suboxone (SCH 000484); Subutex (SCH 028444)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-02-22
    Completion
    2009-12-10
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpiate Dependence; Drug Dependence; Substance Dependence
    InterventionSuboxone (SCH 000484); Subutex (SCH 028444)
    PhasePhase 4
    Registry statusCompleted

  • Incentive-based Smoking Cessation for Methadone Patients

    NCT00718835 · start 2007-06

    Registered record
    Registry ID
    NCT00718835
    Conditions
    Cigarette Smoking Among Patients Currently Receiving Methadone or Buprenorphine Treatment for Opioid Dependence
    Interventions
    incentive-based contingency management
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-06
    Completion
    2013-06
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCigarette Smoking Among Patients Currently Receiving Methadone or Buprenorphine Treatment for Opioid Dependence
    Interventionincentive-based contingency management
    PhasePhase 2
    Registry statusCompleted

  • SSRI and Buprenorphine

    NCT00475878 · start 2006-12

    Registered record
    Registry ID
    NCT00475878
    Conditions
    Opiate Dependence; Depression
    Interventions
    escitalopram; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-12
    Completion
    2009-09
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpiate Dependence; Depression
    Interventionescitalopram; placebo
    PhasePhase 3
    Registry statusCompleted

  • Single Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations

    NCT00388219 · start 2006-10

    Registered record
    Registry ID
    NCT00388219
    Conditions
    Healthy
    Interventions
    Transtec (R) PRO (buprenorphine)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2006-10
    Completion
    2006-11
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTranstec (R) PRO (buprenorphine)
    PhasePhase 1
    Registry statusTerminated

  • Integrating Buprenorphine Into the SFGH AIDS Program

    NCT00263458 · start 2005-12

    Registered record
    Registry ID
    NCT00263458
    Conditions
    HIV; Buprenorphine; Opioid Dependence
    Interventions
    Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-12
    Completion
    2009-06
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Buprenorphine; Opioid Dependence
    InterventionIntegrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting
    PhasePhase 4
    Registry statusCompleted

  • Counseling for Primary Care Office-based Buprenorphine

    NCT00595764 · start 2005-08

    Registered record
    Registry ID
    NCT00595764
    Conditions
    Opiate Dependence
    Interventions
    Manual-guided Physician Management (PM); Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-08
    Completion
    2011-02
    Enrolment
    141

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpiate Dependence
    InterventionManual-guided Physician Management (PM); Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)
    PhasePhase 4
    Registry statusCompleted

  • Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3

    NCT00000328 · start 1997-07

    Registered record
    Registry ID
    NCT00000328
    Conditions
    Heroin Dependence; Opioid-Related Disorders
    Interventions
    Opioid-Related Disorders
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    1997-07
    Completion
    1997-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeroin Dependence; Opioid-Related Disorders
    InterventionOpioid-Related Disorders
    PhasePhase 2
    Registry statusWithdrawn

  • Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users

    NCT00158236 · start 1997-01

    Registered record
    Registry ID
    NCT00158236
    Conditions
    Opioid-Related Disorders
    Interventions
    Buprenorphine; Buprenorphine and Naloxone; Hydromorphone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1997-01
    Completion
    1998-03
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-Related Disorders
    InterventionBuprenorphine; Buprenorphine and Naloxone; Hydromorphone
    PhaseNot applicable
    Registry statusCompleted